Literature DB >> 30165543

Significant Medical and Surgical Morbidity in Perianal Crohn's Disease: Results from a Territory-Wide Study.

Wing Yan Mak1, Oi Sze Mak2, Choon Kin Lee1,3, Whitney Tang1, Wai Keung Leung4, Marc T L Wong5, Alex Shun Fung Sze6, Michael Li7, Chi Man Leung8, Fu Hang Lo9, Belsy C Y Lam10, Kam Hon Chan11, Edwin Hok Shing Shan12, Steven Woon Choy Tsang13, Aric J Hui14, Wai Hung Chow15, Francis K L Chan1, Joseph J Y Sung1, Siew C Ng1.   

Abstract

BACKGROUND: The presence of perianal fistulas in Crohn's disease [CD] denotes increased disease aggressiveness. We studied the epidemiology and clinical outcomes of perianal CD [PCD] using the Hong Kong territory-wide IBD Registry [HKIBDR].
METHODS: Consecutive patients with PCD were identified from the HKIBDR, and disease characteristics, treatments, and outcomes were analysed. The risks for medical and surgical therapies were assessed using Kaplan-Meier analysis.
RESULTS: Among 981 patients with CD with 10530 patient-years of follow-up, 283 [28.8%] had perianal involvement, of which 120 [42.4%] were as first presentation. The mean age at diagnosis of PCD was 29.1 years, and 78.8% were male. The median follow-up duration was 106 months (interquartile range [IQR]: 65-161 months]. Perianal fistula [84.8%] and perianal abscess [52.7%] were the two commonest forms. Male, younger age at diagnosis of CD, and penetrating phenotypes were associated with development of PCD in multivariate analysis. Of 242 patients with fistulizing PCD, 70 [29.2%] required ≥5 courses of antibiotics, and 98 [40.5%] had ≥2 surgical procedures. Nine patients required defunctioning surgery and 4 required proctectomy. Eighty-four patients [34.7%] received biologics. Cumulative probabilities for use of biologics were 4.7%, 5.8%, and 8.6% at 12 months, 36 months, and 96 months, respectively, while the probabilities for surgery were 67.2%, 71.6%, and 77.7%, respectively. Five mortalities were recorded, including 2 cases of anal cancer, 2 CD-related complications, and one case of pneumonia.
CONCLUSION: Over 40% of CD patients presented with perianal disease at diagnosis. Patients with PCD had poor outcome, with young age of onset, multiple antibiotic use, and repeated surgery.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30165543     DOI: 10.1093/ecco-jcc/jjy120

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  7 in total

1.  Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.

Authors:  Mingming Zhu; Xitao Xu; Qi Feng; Zhe Cui; Tianrong Wang; Yunqi Yan; Zhihua Ran
Journal:  Dig Dis Sci       Date:  2020-06-10       Impact factor: 3.199

2.  Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts.

Authors:  Lester Tsai; Jeffrey D McCurdy; Christopher Ma; Vipul Jairath; Siddharth Singh
Journal:  Inflamm Bowel Dis       Date:  2022-10-03       Impact factor: 7.290

3.  Long-term outcomes in perianal fistulizing Crohn's disease in a resource-limited setting: A cohort analysis.

Authors:  Sudheer K Vuyyuru; Pabitra Sahu; Saurabh Kedia; Bhaskar Kante; Peeyush Kumar; Mukesh Kumar Ranjan; Raju Sharma; Govind Makharia; S D Gupta; Peush Sahni; Vineet Ahuja
Journal:  Indian J Gastroenterol       Date:  2020-10-10

4.  Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn's disease: a retrospective cohort study.

Authors:  Ping Zhu; Jin-Fang Sun; Yun-Fei Gu; Hong-Jin Chen; Min-Min Xu; You-Ran Li; Bo-Lin Yang
Journal:  BMC Gastroenterol       Date:  2022-01-10       Impact factor: 3.067

5.  Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis.

Authors:  Gala M Godoy Brewer; George Salem; Muhammad A Afzal; Berkeley N Limketkai; Zadid Haq; Maryam Tajamal; Joanna Melia; Mark Lazarev; Florin M Selaru; Alyssa M Parian
Journal:  BMJ Open Gastroenterol       Date:  2021-12

6.  Perianal and Luminal Relapse Following Perianal Surgical Intervention in Crohn's Disease.

Authors:  Hejun Zhou; Xuehong Wang; Feihong Deng; Pianpian Xia; Zengrong Wu
Journal:  Int J Gen Med       Date:  2021-07-13

Review 7.  Approach to medical therapy in perianal Crohn's disease.

Authors:  Abhinav Vasudevan; David H Bruining; Edward V Loftus; William Faubion; Eric C Ehman; Laura Raffals
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.